The U.S FDA designates Thermo Fisher Scientific's Oncomine Precision Assay a breakthrough device, ET HealthWorld
Thermo Fisher and Oncocyte to Jointly Develop IVD Test Kits and Companion Diagnostic Tests in Precision Oncology - Industry News - mobile.Labmedica.com
Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers | Business
Oncomine Next-Generation Sequencing Solutions for Precision Oncology Research
Oncomine Precision Assay receives breakthrough device designation by the US FDA - Express Pharma
Oncomine Focus Assay | Thermo Fisher Scientific - US
Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Awardees and Opens Spring 2023 Submissions
Thermo Fisher Scientific on LinkedIn: Oncomine BRCA Assay | Thermo Fisher Scientific - US
Thermo Fisher's Oncomine Dx Target Test Receives the US FDA's Approval as a CDx for the Treatment of IDH1-Mutated Cholangiocarcinoma
Thermo Fisher Scientific Launches CE-IVD (IVDD) Next-Generation Sequencing Test and Analysis Software to Expand Access to Precision Oncology Biomarker Testing
Thermo Fisher's Oncomine Dx target test approved in Japan
Thermo Fisher Scientific - Geneuity adds our Oncomine Focus Assay and Ion PGM System to its services. Find out more here: http://ow.ly/PHBRD | Facebook
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test | Technology Networks